Semaglutide can yield weight loss, lower heart issues for at least four years in non-diabetic adults with overweight in Venice, Italy , based on the landmark Semaglutide and Cardiovascular Outcomes trial from the same international author group., examines the long-term weight effects of semaglutide.
"Our long-term analysis of semaglutide establishes that clinically relevant weight loss can be sustained for up to 4 years in a geographically and racially diverse population of adults with overweight and obesity but not diabetes," says Professor Ryan. Similarly, in the semaglutide group, average WHtR fell by 6.9% compared with 1% in the placebo group.
There were no unexpected safety issues with semaglutide in the SELECT trial. The proportion of participants with serious adverse events was lower in the semaglutide group than the placebo group , mainly driven by differences in cardiac disorders . More patients receiving semaglutide discontinued the trial due to gastrointestinal symptoms, including nausea and diarrhea, mainly during the 20-week dose escalation phase.
He adds,"Our findings show that the magnitude of this treatment effect with semaglutide is independent of the amount of weight lost, suggesting that the drug has other actions which lower cardiovascular risk beyond reducing unhealthy body fat. These alternative mechanisms may include positive impacts on blood sugar, blood pressure, or inflammation, as well as direct effects on the heart muscle and blood vessels, or a combination of one or more of these.
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: SkyNews - 🏆 35. / 67 Read more »